Bli medlem
Bli medlem

Du är här


Curetis AG: Curetis Expands Commercial Team

Curetis AG / Curetis Expands Commercial Team. Processed and transmitted by
NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
- Company hires Willem Haagmans as Head of Sales EMEA -

Amsterdam, the Netherlands and Holzgerlingen, Germany, February 3, 2016
-- Curetis N.V. (the "Company
" and, together with Curetis AG, "Curetis
"), a developer of next-level molecular diagnostic solutions, today announced
the expansion of its commercial and general administrative team.

As of February 1, 2016, Willem Haagmans has joined the company as Head of
Sales for the EMEA region.

Willem Haagmans previously worked at Beckman Coulter as General Manager
Benelux. He is a highly experienced commercial executive with a strong track
record, including the successful commercialization of innovative products and
solutions in the molecular diagnostics industry as well as the significant
increase of top-line revenue growth. Among others, Willem Haagmans has held
prior international molecular diagnostics sales management positions with
Roche, Nimblegen, and Vela Diagnostics, bringing extensive leadership
experience with both large and small-to-medium sized molecular diagnostics
companies. He will be based in the Venlo area near the Dutch-German border,
right at the heart of Curetis' European direct sales territories, and will
head all direct sales efforts in DACH, Benelux, France, UK and possibly
Nordic countries.

Curetis' recruiting activities for Key Account Managers, sales team members
and Clinical Application Specialists is well under way in these Western
European markets. Therefore, the company expects to hire additional key
talents in the coming months to further grow its European commercial teams in
sales, marketing and business development.

In addition, Curetis has made further key hires to augment its corporate and
commercial functions:

Bernd Bleile joined on February 1, 2016 as in-house Legal Counsel to provide
additional legal and corporate counsel support for the growing commercial
operations of Curetis.

Dr. Jie Song, a Chinese native with 14 years of working experience in science
and research in Germany and deep scientific and clinical expertise in
microbiology, will join Curetis on March 1, 2016 as Application Specialist
for China and Asia to support Curetis' growing commercial activities in Asia.
With new partnerships and the sale and delivery of 20 Unyvero Analyzers to
its Chinese and ASEAN partners, Curetis in Q4 of 2015 has started to expanded
its commercial reach into Asia. Preparations for a Chinese CFDA clinical
trial are under way and expected to be kicked off in the first half of this

"The recent hires are the first steps to executing and delivering upon our
expansion plans highlighted during our IPO in November 2015," said Oliver
Schacht, CEO of Curetis. "By growing our commercial team and strengthening
our footprint in the EMEA region, we aim at significantly increasing the
number of our direct sales accounts and to continuously grow the installed
base of Unyvero Systems throughout 2016 and beyond."


About Curetis

Founded in 2007, Curetis is a molecular diagnostics company which focuses on
the development and commercialization of reliable, fast and cost-effective
products for diagnosing severe infectious diseases. The diagnostic solutions
of Curetis enable rapid multi-parameter pathogen and antibiotic resistance
marker detection in only a few hours, a process that today can take up to
days or even weeks with other techniques.

To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam
and Euronext Brussels and private equity funds of over EUR 63.5 million. The
company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as
several international distribution agreements covering many countries across
Europe, the Middle East and Asia.

Legal Disclaimer

This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.

The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends", "may", "will",
or "should", and include statements Curetis makes concerning the intended
results of its strategy. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future performance. Curetis'
actual results may differ materially from those predicted by the
forward-looking statements. Curetis undertakes no obligation to publicly
update or revise forward-looking statements, except as may be required by

For further information, please visit

Contact details

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10

International Media&Investor Inquiries

Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media&Investor Inquiries

The Ruth Group
Lee Roth
Tel. +1 646 536 7012



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Curetis AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.